title: Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?
authors.affiliation: Department of Urology, UT Southwestern Medical Center at Dallas, Dallas, TX, USA. yair.lotan@utsouthwestern.edu.
authors.forename: Yair
authors.initials: Y
authors.lastname: Lotan
mesh_terms: D000622:Aminolevulinic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D003558:Cystoscopy; D005260:Female; D006801:Humans; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D017319:Photosensitizing Agents; D016685:Mitomycin; D000622:Aminolevulinic Acid; C419924:5-aminolevulinic acid hexyl ester